Literature DB >> 27832697

The Complete Response to Targeted Drugs Without Surgery or Radiotherapy: A Case of Pituitary Metastasis From Renal Cell Carcinoma.

Mehrdad Payandeh1, Masoud Sadeghi2, Edris Sadeghi2.   

Abstract

Pituitary gland metastasis was seen in elderly patients, and the incidence of pituitary metastasis is 1% to 4% of all cancer patients. Renal cell carcinoma is a primary malignancy in only 2.6% of pituitary metastases. We reported a 50-year-old man with pituitary metastasis from renal cell carcinoma that had signs of diabetes insipidus. He had multiple lesions in both lungs, and bone scan involved L12 and L1 vertebrates. He was treated with combination bevacizumab 600 mg/month and sunitinib 50 mg/D for four weeks with two weeks rest for 6 months. Treatment with targeted drugs without surgery of pituitary or radiotherapy improved metastatic renal cell carcinoma in the patient.

Entities:  

Keywords:  Diabetes insipidus; Pituitary metastasis; Renal cell carcinoma; Sunitinib

Mesh:

Substances:

Year:  2016        PMID: 27832697

Source DB:  PubMed          Journal:  Acta Med Iran        ISSN: 0044-6025


  4 in total

Review 1.  Twelve cases of pituitary metastasis: a case series and review of the literature.

Authors:  Mendel Castle-Kirszbaum; Tony Goldschlager; Benjamin Ho; Yi Yuen Wang; James King
Journal:  Pituitary       Date:  2018-10       Impact factor: 4.107

2.  An unsuspected complication with immune checkpoint blockade: a case report.

Authors:  Lucia Carril-Ajuria; Elisabeth Jiménez-Aguilar; Carlos Gómez-Martín; Carmen Díaz-Pedroche
Journal:  J Med Case Rep       Date:  2018-09-04

3.  Pituitary metastasis: a rare condition.

Authors:  Aida Javanbakht; Massimo D'Apuzzo; Behnam Badie; Behrouz Salehian
Journal:  Endocr Connect       Date:  2018-08-23       Impact factor: 3.335

Review 4.  Giant sellar metastasis from renal cell carcinoma: A case report and literature review.

Authors:  Zhiwei Shen; Chengxian Yang; Xinjie Bao; Renzhi Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.